• Lexicon Pharmaceuticals reported baseline patient characteristics for its pivotal Phase 3 SONATA-HCM trial of sotagliflozin in symptomatic hypertrophic cardiomyopathy.
• Enrollment reached 542 patients, exceeding the 500-patient target, potentially strengthening the study's ability to detect treatment effects.
• Patients had substantial symptoms at entry; their characteristics broadly matched previous studies, supporting relevance to real-world clinical practice.
• Baseline data will be presented October 24, 2026, at the International HCM Summit in Boston.
• Topline results are expected in the first quarter of 2027; the trial covers obstructive and non-obstructive disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230830PRIMZONEFULLFEED9851856) on October 23, 2026, and is solely responsible for the information contained therein.